Fentanyl (Sublimaze) Dosing Cheat Sheet for Adults and Peds    body {font-family: 'Open Sans', sans-serif;}

### Fentanyl (Sublimaze) Dosing Cheat Sheet for Adults and Peds

**Fentanyl Adult doses** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Purpose | Route and dose |
| --- | --- |
| Provide analgesia | 0.5 - 1 mcg/kg/dose IV (low doses) |
| Non-weight based for adults | 50 - 100 mcg as needed |
| Induction with concomitant administration of propofol  
Elderly and poor-risk patients | 50 to 100 IV initially, repeat as needed  
  
A reduced dose of 25 to 50 mcg |
| **Intraoperative maintenance:**  
When there is patient movement and/or changes in vital signs indicate surgical stress or lightening of analgesia. | 25 to 50 mcg IV as needed |
| As the sole surgical anesthesia agent | 50 to 150 mcg/kg IV (large dose) |
| Adjunct to regional anesthesia when additional analgesia is required.  
Repeat in one or two hours as needed | 50 to 100 mcg IV |
| **Post-op:** Control of pain, tachypnoea, and emergence delirium. | 50 to 100 mcg IV |
| **Induction for open heart procedures** | 10-20 mLs (500 - 1,000 mcg)  
**Low induction dose:** 1-5 mcg/kg (with Etomidate)  
**Medium dose:** 20-40 mcg/kg (with Etomidate)  
**Large dose:** 100 mcg/kg (often without Etomidate) |
| **Intrathecal** | 25 mcg |
| **Epidural**  
Not FDA-approved for epidural use in the U.S., but commonly used clinically. | 10 - 30 mcg/kg Q 10 minutes |
| **Transdermal fentanyl patch:**  
Peak plasma fentanyl concentrations in about 18 hours.  
For chronic pain patients and not administered preoperatively. | 75 to 100 mcg/hour |

  
**Pediatric Fentanyl dosing** table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

| Route of administration | Dosing |
| --- | --- |
| Intraoperative maintenance | 1-2 mcg/kg (total) |
| IV bolus for analgesia | 1-2 mcg/kg |
| IV bolus loading dose | 5-10 mcg/kg |
| IV continuous infusion | 1-3 mcg/kg/hr |
| Intranasal | 1-2 mcg/kg |
| **Heart surgery:** To maintain cardiovascular homeostasis | 10-100 mcg/kg |
| ACTIQ (lozenge) | 200 mcg, 400 mcg, 600 mcg, 800 mcg, or 1,600 mcg  
Compressed lozenge with integral oromucosal applicator.  
Adolescents aged 16 years and above for breakthrough cancer pain.  
Lack of safety and efficacy for ages < 16 years  
One lozenge contains approximately 1.89 g glucose and 20-36 mg sucrose. |
| OTFC (oral transmucosal fentanyl citrate)  
(Lollipop) | 5-15 mcg/kg  
High incidence of preoperative nausea and vomiting  
No longer available in the US |

  
  

Stoelting’s Pharmacology & Physiology in Anesthetic Practice 6 th Ed., 2022, pages 214-223  
Pamela Flood, James P. Rathmell, and Richard D. Urman  
  
Smith’s Anesthesia for Infants and Children 8 th Ed. 2021, pages 241-244.  
Peter J. Davis, Franklin P Cladis and Etsuro K. Motoyama  
  
Colte and Lerman’s A Practice of Anesthesia for Infants and Children _5 th Ed. 2018, Pages.157-59  
_Charles J. Cote’, Jarrold Lerman and Brian J. Anderson  
  
Fentanyl  
DrugBank Online: (accessed 06/2022)  
https://go.drugbank.com/drugs/DB00813  
  
Fentanyl Transdermal  
StatPearls (accessed 06/2022)  
Katherine P. Taylor; Karampal Singh; Amandeep Goyal.  
https://www.ncbi.nlm.nih.gov/books/NBK555968/  
DURAGESICÒ (fentanyl transdermal system), CII (Package Insert)  
AccessData FDA (accessed 06/2022)  
https://www.accessdata.fda.gov/drugsatfda\_docs/label/2021/019813s081lbl.pdf  
  
Pharmacokinetics of non-intravenous formulations of fentanyl  
Clinical Pharmacokinetics, 2013 Jan;52(1):23-36.  
Jörn Lötsch,Carmen Walter, Michael J Parnham, Bruno G Oertel, Gerd Geisslinger  
  
Fentanyl  
StatPearls Accessed 06/202)  
Carlos F. Ramos-Matos; Karlyle G. Bistas; Wilfredo Lopez-Ojeda.  
https://www.ncbi.nlm.nih.gov/books/NBK459275/